Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues:
Product sales	$ 8,550	$ 7,125	$ 17,575	$ 12,825
Lease income from a related party	23	37	60	73
Total revenues	8,573	7,162	17,635	12,898
Costs of revenues:
Cost of goods sold	1,865	1,537	3,842	2,774
Royalty fee	1,685	1,445	3,466	2,566
Total costs of revenues	3,550	2,982	7,308	5,340
Gross Profit	5,023	4,180	10,327	7,558
Operating expenses:
Research and development	3,851	2,255	7,843	7,513
General and administrative	5,520	5,488	10,845	10,990
Selling and marketing	3,398	3,360	6,675	6,075
Acquired in-process research and development	0	1,055	0	6,555
Total operating expenses	12,769	12,158	25,363	31,133
Loss from operations	(7,746)	(7,978)	(15,036)	(23,575)
Non-operating income (expense):
Interest income, net	40	76	114	182
Other income	11	33	49	53
Foreign exchange gain	1,355	76	1,688	295
Change in fair value of investments	(1,153)	1,914	(2,708)	3,482
Impairment loss of long-term investments		(865)		(865)
Loss before income tax expense	(7,493)	(6,744)	(15,893)	(20,428)
Net loss	(7,493)	(6,744)	(15,893)	(20,428)
Less: loss attributable to redeemable noncontrolling interest	(548)	(317)	(965)	(666)
Accretion to redeemable noncontrolling interest redemption value	735	519	1,348	1,067
Net loss attributable to CASI Pharmaceuticals, Inc.	$ (7,680)	$ (6,946)	$ (16,276)	$ (20,829)
Net loss per share (basic)	$ (0.56)	$ (0.50)	$ (1.19)	$ (1.57)
Net loss per share (diluted)	$ (0.56)	$ (0.50)	$ (1.19)	$ (1.57)
Weighted average number of common stock outstanding (basic)	13,606,130	13,979,636	13,700,282	13,235,128
Weighted average number of common stock outstanding (diluted)	13,606,130	13,979,636	13,700,282	13,235,128
Comprehensive loss:
Net loss	$ (7,493)	$ (6,744)	$ (15,893)	$ (20,428)
Foreign currency translation adjustment	(3,541)	1,005	(3,293)	833
Total comprehensive loss	(11,034)	(5,739)	(19,186)	(19,595)
Less: Comprehensive loss attributable to redeemable noncontrolling interest	(1,800)	14	(2,144)	(403)
Comprehensive loss attributable to common stockholders	$ (9,234)	$ (5,753)	$ (17,042)	$ (19,192)